HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pimm, M. V. Articles by Baldwin, R. W. Search for Related Content PubMed PubMed Citation Articles by Pimm, M. V. Articles by Baldwin, R. W.

The Characteristics of Blood-Borne Radiolabels and the Effect of Anti-Mouse IgG Antibodies on Localization of Radiolabeled Monoclonal Antibody in Cancer Patients

Cancer Research Campaign Laboratories, University of Nottingham
Department of Medical Physics, University Hospital
Department of Surgery, University Hospital, Nottingham, UK

Correspondence: For reprints contact: Malcolm V. Pimm, PhD, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, NG7 2RD, UK.

ABSTRACT

Quantitative and qualitative aspects of the blood survival of ¹³¹I and ¹¹¹In-labeled monoclonal antibody 791T/36 have been examined in patients with colo-rectal carcinoma, ovarian carcinoma and osteogenic sarcoma who were receiving labeled antibody in diagnostic immunoscintigraphy trials. The blood clearance of intact antibody radiolabeled with either ¹³¹I or ¹¹¹ln was similar. A bi-phasic decline of both radiolabeled preparations was measured with initial half-lives 0.62 and 0.42 days for ¹³¹I and ¹¹¹In labels and then with 1.85 and 1.40 day half-lives, respectively. The Fab fragment of the antibody was lost more rapidly (initial half-life 0.20 days and then 0.78 days). Blood-borne radioactivity was associated predominantly with plasma rather than cellular elements. Radioactivity was still attached to undegraded, uncomplexed, and immunologically active antibody as demonstrated by molecular filtration, immune precipitation, and antigen binding assays. However, anti-mouse-IgG antibody detected within 7 days of administration of radiolabeled antibody was present for at least 10 mo and has implications for the efficiency of repeated image studies.

This article has been cited by other articles:

				J. Y. C. Wong, D. Z. Chu, L. E. Williams, D. M. Yamauchi, D. N. Ikle, C. S. Kwok, A. Liu, S. Wilczynski, D. Colcher, P. J. Yazaki, et al. Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5014 - 5021. [Abstract] [Full Text] [PDF]

				R. B. Mandell, L. Z. Mandell, and C. J. Link Jr. Radioisotope Concentrator Gene Therapy Using the Sodium/Iodide Symporter Gene Cancer Res., February 1, 1999; 59(3): 661 - 668. [Abstract] [Full Text] [PDF]